Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methoxyacetic Acid SCHEMBL4409509 | 0.94 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Methoxyacetic Acid SCHEMBL338718 | 0.94 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Methoxyacetic Acid SCHEMBL18169478 | 0.94 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Methoxyacetic Acid SCHEMBL3796356 | 0.94 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Methoxyacetic Acid SCHEMBL11767030 | 0.94 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Methoxyacetic Acid SCHEMBL5860341 | 0.94 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Methoxyacetic Acid SCHEMBL5903057 | 0.94 | — | — | |
| Methoxyacetic Acid SCHEMBL630881 | 0.94 | — | — | |
| Methoxyacetic Acid SCHEMBL4408238 | 0.94 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Methoxyacetic Acid SCHEMBL5050299 | 0.94 | CA4 (0.37) | CA4FFAR3HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984745-B2 | Environmentally benign lead zirconate titanate ceramic precursor materials | RAYTHEON COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050168916-A1 | Environmentally benign lead zirconate titanate ceramic precursor materials | RAYTHEON COMPANY | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050168916-A1 | Environmentally benign lead zirconate titanate ceramic precursor materials | SLC39A11, SOST, ZRANB2 | CA4 1783/4885FFAR3 4329/4885HDAC3 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.